1-14 of 14
John A. Thompson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

Open Access
Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Ferry A.L.M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J. Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Ken Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B. El-Khoueiry
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 71–83.
https://doi.org/10.1158/1078-0432.CCR-21-0845
Published: 01 January 2022
View articletitled, A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Open the PDF for A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Available to Purchase
Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5086–5091.
https://doi.org/10.1158/1078-0432.CCR-20-0177
Published: 01 October 2020
View articletitled, Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Open the PDF for Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B in another window
Includes: Supplementary data
Journal Articles

Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

Free
John A. Thompson, Robert J. Motzer, Ana M. Molina, Toni K. Choueiri, Elisabeth I. Heath, Bruce G. Redman, Randeep S. Sangha, D. Scott Ernst, Roberto Pili, Stella K. Kim, Leonard Reyno, Aya Wiseman, Fabio Trave, Banmeet Anand, Karen Morrison, Fernando Doñate, Christian K. Kollmannsberger
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (18): 4399–4406.
https://doi.org/10.1158/1078-0432.CCR-18-0481
Published: 14 September 2018
View articletitled, Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Open the PDF for Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Free
Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1805–1815.
https://doi.org/10.1158/1078-0432.CCR-17-3436
Published: 12 April 2018
View articletitled, Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Open the PDF for Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

Free
Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish R. Patel, Holbrook E.K. Kohrt, John A. Thompson, Paul M. Sondel, Heather A. Wakelee, Mary L. Disis, Judith C. Kaiser, Martin A. Cheever, Howard Streicher, Steven P. Creekmore, Thomas A. Waldmann, Kevin C. Conlon
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1525–1535.
https://doi.org/10.1158/1078-0432.CCR-17-2451
Published: 02 April 2018
View articletitled, A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors in another window
Journal Articles

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

Free
Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie R. Gralow, Peggy Porter, Rosa F. Yeh, Vijayakrishna K. Gadi, Jamie Guenthoer, Jan H. Beumer, Larissa Korde, Sandra Strychor, Brian F. Kiesel, Hannah M. Linden, John A. Thompson, Elizabeth Swisher, Xiaoyu Chai, Stacie Shepherd, Vincent Giranda, Jennifer M. Specht
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2855–2864.
https://doi.org/10.1158/1078-0432.CCR-15-2137
Published: 14 June 2016
View articletitled, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer
Open the PDF for Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

Free
Mayer N. Fishman, John A. Thompson, Gregory K. Pennock, Rene Gonzalez, Luz M. Diez, Adil I. Daud, Jeffery S. Weber, Bee Y. Huang, Shamay Tang, Peter R. Rhode, Hing C. Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7765–7775.
https://doi.org/10.1158/1078-0432.CCR-11-1817
Published: 18 December 2011
View articletitled, Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies
Open the PDF for Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies in another window
Journal Articles

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Free
Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman, John A. Thompson, Piotr Tomczak, Cezary Szczylik, Mike McDonald, Sarah Eastty, William H. Shingler, Jackie de Belin, Madusha Goonewardena, Stuart Naylor, Richard Harrop
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (22): 5539–5547.
https://doi.org/10.1158/1078-0432.CCR-10-2082
Published: 14 November 2010
View articletitled, Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Open the PDF for Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study in another window
Journal Articles

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Free
Kazuo Koyanagi, Steven J. O'Day, Peter Boasberg, Michael B. Atkins, He-Jing Wang, Rene Gonzalez, Karl Lewis, John A. Thompson, Clay M. Anderson, Jose Lutzky, Thomas T. Amatruda, Evan Hersh, Jon Richards, Jeffrey S. Weber, Dave S.B. Hoon
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2402–2408.
https://doi.org/10.1158/1078-0432.CCR-10-0037
Published: 14 April 2010
View articletitled, Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma
Open the PDF for Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma in another window
Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Free
Jeffrey Weber, John A. Thompson, Omid Hamid, David Minor, Asim Amin, Ilan Ron, Ruggero Ridolfi, Hazem Assi, Anthony Maraveyas, David Berman, Jonathan Siegel, Steven J. O'Day
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5591–5598.
https://doi.org/10.1158/1078-0432.CCR-09-1024
Published: 31 August 2009
View articletitled, A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Open the PDF for A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma in another window
Includes: Supplementary data
Journal Articles

C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients

Free
Scott S. Tykodi, Nobuharu Fujii, Nathalie Vigneron, Sharon M. Lu, Jeffrey K. Mito, Maureen X. Miranda, Jeffrey Chou, Lilien N. Voong, John A. Thompson, Brenda M. Sandmaier, Peter Cresswell, Benoît Van den Eynde, Stanley R. Riddell, Edus H. Warren
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5260–5269.
https://doi.org/10.1158/1078-0432.CCR-08-0028
Published: 12 August 2008
View articletitled, C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients
Open the PDF for C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients in another window
Includes: Supplementary data
Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens

Free
Scott S. Tykodi, Edus H. Warren, John A. Thompson, Stanley R. Riddell, Richard W. Childs, Brith E. Otterud, Mark F. Leppert, Rainer Storb, Brenda M. Sandmaier
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (23): 7799–7811.
https://doi.org/10.1158/1078-0432.CCR-04-0072
Published: 07 December 2004
View articletitled, Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens
Open the PDF for Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens in another window
Journal Articles

A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma

Free
John A. Thompson, Robert A. Figlin, Christi Sifri-Steele, Ronald J. Berenson, Mark W. Frohlich
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 3562–3570.
Published: 23 September 2003
View articletitled, A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma in another window
Journal Articles

Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma

Free
Alison T. Stopeck, Amanda Jones, Evan M. Hersh, John A. Thompson, Deborah M. Finucane, John C. Gutheil, Rene Gonzalez
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2285–2291.
Published: 01 August 2001
View articletitled, Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma
Open the PDF for Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma in another window